Medical device company, Neuromod Devices Ltd, announced that it has launched Ótologie, a “specialist telehealth service for tinnitus.” This new service will provide tinnitus patients, throughout the United Kingdom and Europe, with a private care option to avoid waiting lists and give them immediate access to treatment from its telehealth service.
To mark Tinnitus Week (February 1-7, 2021), The British Irish Hearing Instrument Association (BIHIMA) announced the results of a survey that questioned its research panel of UK audiologists on the subject of tinnitus awareness.
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
CILcare, a preclinical provider in otology, will hold a free webinar on July 9 at 8 pm (CEST) called “How to Assess Drug Candidates on Tinnitus Preclinical Models For a Successful Transition to Clinical Trials.”
The trial reportedly achieved its objectives by demonstrating a positive clinical signal for OTO-313 based on a TFI responder analysis, with a favorable safety profile, according to the company.
The issue can be found online and provides a variety of resources and real-life advice for managing mental health during tumultuous times.